Aernoud Fiolet

125 Colchicine in Patients with Chronic Coronary Disease Table 1. Characteristics of the Trial Patients at Baseline.* Characteristic Colchicine (N=2762) Placebo (N=2760) Age — yr 65.8±8.4 65.9±8.7 Female sex — no. (%) 457 (16.5) 389 (14.1) Country — no. (%) Australia 951 (34.4) 953 (34.5) The Netherlands 1811 (65.6) 1807 (65.5) Current smoker — no. (%)† 318 (11.5) 330 (12.0) Hypertension — no. (%) 1421 (51.4) 1387 (50.3) Diabetes — no. (%) Patients receiving any treatment for diabetes 492 (17.8) 515 (18.7) Patients dependent on insulin 140 (5.1) 147 (5.3) Renal function — no. (%)‡ Stage 1 or 2 2614 (94.6) 2602 (94.3) Stage 3a 148 (5.4) 158 (5.7) Prior acute coronary syndrome — no. (%) 2323 (84.1) 2335 (84.6) Time since last acute coronary syndrome — no. (%) ≤24 mo 753 (27.3) 726 (26.3) >24 mo 1570 (56.8) 1609 (58.3) Prior coronary revascularization — no. (%) 2301 (83.3) 2320 (84.1) Coronary-artery bypass grafting 319 (11.5) 391 (14.2) Percutaneous coronary intervention 2100 (76.0) 2077 (75.3) History of atrial fibrillation — no. (%) 332 (12.0) 317 (11.5) History of gout — no. (%) 220 (8.0) 226 (8.2) Medication use — no. (%) Single antiplatelet therapy 1849 (66.9) 1852 (67.1) Dual antiplatelet therapy 638 (23.1) 642 (23.3) Anticoagulant 342 (12.4) 330 (12.0) No antiplatelet agent or anticoagulant 4 (0.1) 11 (0.4) Statin 2594 (93.9) 2594 (94.0) Ezetimibe 551 (19.9) 522 (18.9) Any lipid-lowering agent 2670 (96.7) 2665 (96.6) Renin–angiotensin inhibitor 1995 (72.2) 1965 (71.2) Beta-blocker 1692 (61.3) 1735 (62.9) Calcium-channel blocker 633 (22.9) 611 (22.1) * Plus–minus values are means ±SD. † Information on smoking was missing for 21 patients. ‡ Stage 1 refers to an estimated glomerular filtration rate of at least 90 ml per minute per 1.73 m² of body-surface area (normal or high), stage 2 to a rate of 60 to 89 ml per minute per 1.73 m² (mildly decreased), and stage 3a to a rate of 45 to 59 ml per minute per 1.73 m² (mildly to moderately decreased). Stages are based on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. 14